Clinical Trial Update: Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO [Phase 4]

View source ↗

Summary

Phase 4 clinical trial updating the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with tumor-induced osteomalacia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tumor-induced Osteomalacia

Drugs mentioned

• KRN23 (burosumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Tumor-Induced Osteomalacia (TIO) | Phase 4 | Status: COMPLETED